Eloquest Healthcare and Vancive Medical Technologies Launch Antimicrobial Post-Operative Dressings

Vancive Medical Technologies™, an Avery Dennison (NYSE:AVY) business, and Eloquest Healthcare®, Inc. have partnered to develop an innovative post-operative dressing that contains an antimicrobial agent called chlorhexidine gluconate (CHG). The antimicrobial properties of CHG inhibit microbial growth within the dressing.

CHG is extremely difficult to incorporate in an absorbent adhesive dressing, making the development of the BeneHold™ CHG platform a significant technical accomplishment for Vancive. The Eloquest Healthcare ReliaTect™ Post-Op Dressings with CHG are the first to combine CHG in an absorbent, transparent and waterproof design.

“ReliaTect post-operative dressings are a natural fit for our BeneHold CHG platform, and the needs of patients and clinicians,” said Kirsten Newquist, general manager for Vancive Medical Technologies. “We look forward to further expanding our CHG technology to many more applications.”

ReliaTect is available in small and large sizes with a transparent window for surgical site visualization, and a nonwoven border that facilitates dressing application and provides additional securement during wear. The dressings comfortably adhere to the skin, absorb fluids and protect the site from external contaminants.

“Chlorhexidine Gluconate (CHG) is a trusted antiseptic in pre-operative site treatment,” said Tim O’Halla, president and CEO for Eloquest Healthcare. “By combining its antimicrobial properties with the sustained transparency and absorbency of our ReliaTect Post-Op Dressings, we are bringing to market a truly patient friendly post-operative dressing with proven antimicrobial activity.”

ReliaTect Post-Op Dressings with CHG are now commercially available from Eloquest Healthcare in the United States. The device received 510(k) clearance from the FDA in March and is now available nationwide. Eloquest Healthcare is the exclusive distributor of the dressings in the United States and Canada.
http://news.averydennison.com/press-release/corporate/eloquest-healthcare-and-vancive-medical-technologies-launch-antimicrobial-po

Related Posts

Sappi delivers solid results in difficult economic climate

Financial summary for the quarter *EBITDA excluding special items US$156 million (Q1 FY23 US$290 million) *Net debt US$1,216 million (Q1 FY23 US$1,241 million) *EPS excluding special items 8 US cents (Q1 FY23 30 US cents) *Production at Stockstadt and Lanaken Mills in Europe permanently ceased

Lenzing welcomes new core shareholder Suzano S/A

The Lenzing Group, a leading supplier of regenerated cellulose fibers for the textile and nonwovens industries, learned today that Lenzing's main shareholder B&C Group and the Brazilian pulp producer Suzano S/A have signed a long-term partnership in connection with the majority stake in Lenzing. As part of this agreement, Suzano S/A will take over a 15 percent stake in Lenzing AG from B&C Group. Suzano is the world's largest pulp producer based in Sao Paolo and recently achieved annual sales of more than EUR 7 billion. Lenzing's management welcomes the proposed transaction and looks forward working with another core shareholder.

Orchids Paper Products Company Announces Fourth Quarter And Full Year 2017 Results

Fourth Quarter 2017 Relative to Third Quarter 2017: Net sales of $43.5 million in the fourth quarter decreased $1.7 million, or 3.7%, from the third quarter driven by seasonality factors. Converted product sales declined $1.5 million; a decline of $1.9 million due to volume, offset by higher average-selling prices having a positive impact of $0.4 million. Parent roll sales decreased $0.2 million, as the effect of lower sales volume outpaced an increase in the average selling price compared to third quarter 2017. Average selling prices were, to a degree, positively impacted in the fourth quarter by the inclusion of Orchids' new ultra-premium products manufactured at Barnwell. Cost of goods sold, net of depreciation, in the fourth quarter declined by $2.5 million to 84.6% of net sales, down from 87.0% in the third quarter, representing our second consecutive decline as a percentage of sales. Total cost of sales increased to 94.2% of revenue in the fourth quarter, up from 93.9% in the third quarter. Total depreciation increased to 9.6% of net sales in the fourth quarter from 6.9% of net sales in the third quarter as a result of the addition of the Barnwell facility. Click Read More below for additional information.
Back To Top
×Close search
Search